Efficacy and Safety of Guselkumab in Patients With Active Psoriatic Arthritis who are Inadequate Responders to Tumor Necrosis Factor Inhibitors: Results Through One Year of a Phase 3b, Randomized, Controlled Study (COSMOS)

COATES L., Gossec L., Theander E., Bergmans P., Neuhold M., Karyekar CS., Shawi M., Noel W., Schett G., McInnes IB.

Type

Journal article

Journal

Annals of the rheumatic diseases

Publisher

BMJ Publishing Group

Publication Date

22/10/2021

Permalink